Chitosan-based crosslinking for controlled topical drug release in rhinosinusitis

IF 7.2 2区医学 Q1 OTORHINOLARYNGOLOGY

International Forum of Allergy & Rhinology Pub Date : 2024-07-11 DOI:10.1002/alr.23413

Do-Yeon Cho MD, Dong Jin Lim PhD, Olivia J. Kelly, Daniel Skinner BS, Shaoyan Zhang PhD, Martin P. Jones BS, Jessica Grayson MD, Bradford A. Woodworth MD

引用次数: 0

Abstract

Key points

Chitosan is a promising drug delivery vector for therapeutics owing to its biocompatibility.
Once crosslinked with chitosan, prolonged drug release was noted regardless of hydrophilicity.
Hydrophilic drugs may require different strategies to obtain a sustained release profile.

查看原文本刊更多论文

基于壳聚糖的交联技术用于鼻炎的局部控释药物。

要点：壳聚糖具有生物相容性，是一种很有前景的药物输送载体。与壳聚糖交联后，无论亲水性如何，药物释放时间都会延长。亲水性药物可能需要不同的策略才能获得持续释放特性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Forum of Allergy & Rhinology OTORHINOLARYNGOLOGY-

CiteScore

11.70

自引率

10.90%

发文量

185

审稿时长

6-12 weeks

期刊介绍： International Forum of Allergy & Rhinologyis a peer-reviewed scientific journal, and the Official Journal of the American Rhinologic Society and the American Academy of Otolaryngic Allergy. International Forum of Allergy Rhinology provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions. The application of current research to the management of otolaryngic allergy, rhinologic, and skull base diseases and the need for further investigation will be highlighted.